The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2015 | Targeting the survival cascade of B-cells in lymphoid malignancies
Wyndham Wilson
• 4 Dec 2015
Wyndham Wilson, MD, PhD from the National Cancer Institute, Bethesda, MD talks about drugs that have been developed to indirectly target BCR, such as venetoclax (ABT-199), a Bcl-2 inhibitor; drugs targeting transcription factors, called bromodomain inhibitors, targeting MYC and NF-kappaB.
